Related to Roche Outlines $5.7B Bid to Buy Illumina for $44.5 Per Share in Cash

• Presidential Panel Expected to Sort Out Ethics of Clinical Sequencing, According to GEN Poll
  
• Academia-Industry Project Secures $38.7M for Autism Spectrum Disorders
  
• Preamplified Nanopore Senses Briefest Signals Generated by High-Speed DNA
  
• Biological Nanopore Sequencing Platform Reads DNA at Single-Nucleotide Resolution
  
• Affymetrix to Distribute Almac’s Expression-Profiling Array for FFPE Samples
  
• Roche Plans 2012 Filing for Breast Cancer Antibody-Drug Conjugate
  
• Asuragen to Receive $6.8M from the Cancer Prevention and Research Institute of Texas
  
• New York Genome Center Gets $3M from Sloan Foundation
  
• GE Snags Sequencing Services Firm SeqWright
  
• Seattle, Millennium Tap Ventana to Develop Companion Dx for Lymphoma Drug
  
• Roche Reports Sales Dip in First Quarter of This Year
  
• OncoMed Taps Genomic Health to Identify Predictive Biomarkers for Anticancer Antibodies
  
• Oxford Nanopore to Pocket £31.4M to Advance Single-Molecule Detection Technology
  
• Roche Terminates Pivotal Heart Disease Study with Dalcetrapib
  
• Macrogen Taps into PerkinElmer’s Sample Prep Solutions for Next-Gen Sequencing
  
• 454, SoftGenetics Enter Co-Promotion Deal in Next-Gen Sequencing Informatics
  
• Six Suitors Join Bristol-Myers in Considering a Bid for Amylin
  
• Sequencing Study Suggests How VRSA Evolves Independently in Each Patient
  
• ThromboGenics, BioInvent Regain TB-403 from Roche and Ditch Anticoagulant TB-402
  
• FDA Clears Roche’s Perjeta as Combination Therapy for Metastatic Breast Cancer